• Publications
  • Influence
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial
TLDR
This pragmatic trial suggests that clinically meaningful antipsychotic treatment of first-episode of schizophrenia is achievable, for at least 1 year, but it cannot conclude that second-generation drugs are more efficacious than is haloperidol, since discontinuation rates are not necessarily consistent with symptomatic improvement. Expand
Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.
TLDR
In terms of both safety and efficacy, symptomatically stable patients with schizophrenia benefit from being switched to long-acting injectable risperidone, and Severity of symptoms of schizophrenia was improved in each group. Expand
Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
TLDR
Aripiprazole-IM-depot significantly delayed time to impending relapse compared with placebo and appears to be a well-tolerated maintenance treatment option for schizophrenia. Expand
Metabolic side effects of antipsychotic medication
TLDR
The use of second‐generation antipsychotics is associated with metabolic side effects including weight gain, diabetes mellitus and an atherogenic lipid profile, which may also impair the patient's adherence to treatment. Expand
Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial.
TLDR
Combining aripiprazole and clozapine resulted in significant weight, BMI and fasting cholesterol benefits to patients suboptimally treated with clozAPine and there were no significant differences in Positive and Negative Syndrome Scale total score changes between groups. Expand
Compliance with antipsychotic treatment
TLDR
Different factors influencing compliance are reviewed and possibilities to enhance compliance among schizophrenic patients are discussed. Expand
Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study
TLDR
Aripiprazole once-monthly 400mg was non-inferior to oral aripipazole, and the reduction in Kaplan–Meier estimated impending relapse rate at week 26 was statistically significant. Expand
World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia
TLDR
There were substantial differences among both first- and second- generation antipsychotic agents with regard to their propensity to cause extrapyramidal, metabolic and other adverse effects; second-generation agents have a lower liability to cause acute extrapYramidal symptoms and tardive dyskinesia along with a tendency to cause greater metabolic side-effects than first-generationagents. Expand
Normative data for functional assessment of cancer therapy General scale and its use for the interpretation of quality of life scores in cancer survivors
TLDR
Survivors of Hodgkin's disease were found to have higher functional and social well-being scores than those of the general population sample and Sociodemographic variables should always be taken into consideration when interpreting QOL scores. Expand
Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study
TLDR
PP3M was noninferior to PP1M: relapse rates were similar in both groups and increased weight was the most common treatment-emergent adverse event (double-blind phase; 21% each). Expand
...
1
2
3
4
5
...